化学
芳基
KEAP1型
生物化学
立体化学
转录因子
有机化学
基因
烷基
作者
Tom D. Heightman,James F. Callahan,Elisabetta Chiarparin,Joseph E. Coyle,Charlotte M. Griffiths‐Jones,Ami S. Lakdawala,Rachel McMenamin,Paul N. Mortenson,David L. Norton,Torren M. Peakman,Sharna J. Rich,Caroline J. Richardson,William L. Rumsey,Yolanda Sánchez,Gordon Saxty,Henriëtte M. G. Willems,Lawrence A. Wolfe,Alison J.‐A. Woolford,Zining Wu,Yan Huang,Jeffrey K. Kerns,Thomas G. Davies
标识
DOI:10.1021/acs.jmedchem.9b00279
摘要
The KEAP1–NRF2-mediated cytoprotective response plays a key role in cellular homoeostasis. Insufficient NRF2 signaling during chronic oxidative stress may be associated with the pathophysiology of several diseases with an inflammatory component, and pathway activation through direct modulation of the KEAP1–NRF2 protein–protein interaction is being increasingly explored as a potential therapeutic strategy. Nevertheless, the physicochemical nature of the KEAP1–NRF2 interface suggests that achieving high affinity for a cell-penetrant druglike inhibitor might be challenging. We recently reported the discovery of a highly potent tool compound which was used to probe the biology associated with directly disrupting the interaction of NRF2 with the KEAP1 Kelch domain. We now present a detailed account of the medicinal chemistry campaign leading to this molecule, which included exploration and optimization of protein–ligand interactions in three energetic "hot spots" identified by fragment screening. In particular, we also discuss how consideration of ligand conformational stabilization was important to its development and present evidence for preorganization of the lead compound which may contribute to its high affinity and cellular activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI